Effect of COMT Val158Met genotype on nicotine withdrawal-related cognitive dysfunction in smokers with and without schizophrenia

Schizophrenia Research

Volumn 150, Issue 2-3, 2013, Pages 602-603

  Wing, Victoria C ^a,d   Tang, Yi Lang ^b   Sacco, Kristi A ^c   Cubells, Joseph F ^b,c   George, Tony P ^a,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHIONINE; VALINE;

ALLELE; COGNITIVE DEFECT; COMT GENE; CONTROLLED STUDY; DEPTH PERCEPTION; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; MENTAL TASK; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING CESSATION; TASK PERFORMANCE; WITHDRAWAL SYNDROME; WORKING MEMORY;

ANALYSIS OF VARIANCE; CATECHOL O-METHYLTRANSFERASE; FEMALE; GENOTYPE; HUMANS; MALE; METHIONINE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; TOBACCO USE DISORDER; VALINE;

EID: 84886295413     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.09.005     Document Type: Letter

References (9)

1. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 2004, 75(5):807-821.
2. Dolan S.L., Sacco K.A., Termine A., Seyal A.A., Dudas M.M., Vessicchio J.C., Wexler B.E., George T.P. Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophr. Res. 2004, 70(2-3):263-275.
3. 108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(12):6917-6922.
4. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6(3):243-250.
5. Loughead J., Wileyto E.P., Valdez J.N., Sanborn P., Tang K., Strasser A.A., Ruparel K., Ray R., Gur R.C., Lerman C. Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. Mol. Psychiatry 2009, 14(8):820-826.
6. Malhotra A.K., Kestler L.J., Mazzanti C., Bates J.A., Goldberg T., Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am. J. Psychiatry 2002, 159(4):652-654.
7. 108/158Met genotype with smoking cessation. Pharmacogenet. Genomics 2008, 18(2):121-128.
8. Sacco K.A., Termine A., Seyal A., Dudas M.M., Vessicchio J.C., Krishnan-Sarin S., Jatlow P.I., Wexler B.E., George T.P. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch. Gen. Psychiatry 2005, 62(6):649-659.
9. Wing V.C., Wass C.E., Soh D.W., George T.P. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann. N. Y. Acad. Sci. 2012, 248(1):89-106.